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Abstract
The interferon-induced transmembrane (IFITM) protein family is a group of antiviral restric-
tion factors that impair flexibility and inhibit membrane fusion at the plasma or the endoso-
mal membrane, restricting viral progression at entry. While IFITMs are widely known to
inhibit several single-stranded RNA viruses, there are limited reports available regarding
their effect in double-stranded DNA viruses. In this work, we have analyzed a possible anti-
viral function of IFITMs against a double stranded DNA virus, the African swine fever virus
(ASFV). Infection with cell-adapted ASFV isolate Ba71V is IFN sensitive and it induces
IFITMs expression. Interestingly, high levels of IFITMs caused a collapse of the endosomal
pathway to the perinuclear area. Given that ASFV entry is strongly dependent on endocyto-
sis, we investigated whether IFITM expression could impair viral infection. Expression of
IFITM1, 2 and 3 reduced virus infectivity in Vero cells, with IFITM2 and IFITM3 having an
impact on viral entry/uncoating. The role of IFITM2 in the inhibition of ASFV in Vero cells
could be related to impaired endocytosis-mediated viral entry and alterations in the choles-
terol efflux, suggesting that IFITM2 is acting at the late endosome, preventing the decapsi-
dation stage of ASFV.
Introduction
Upon infection with pathogens such as bacteria or viruses, the host cell activates the innate
immune response as a first line of defense. The group of cytokines known as interferons (IFN)
plays a major role in the cell immunity by inducing a cascade of interferon-stimulated genes
(ISGs) that encode for several antiviral innate immune effectors. Among ISGs, the interferon-
induced transmembrane proteins (IFITMs) are known to inhibit entry of a wide variety of
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enveloped RNA viruses [1]. This group of proteins is present across a wide range of species:
from amphibians, fish and birds to mammals. IFITMs in humans were identified 26 years ago
as interferon-stimulated genes upon induction of type-I and type-II IFN [2, 3]. Human
IFITM1, IFITM2 and IFITM3 are expressed in almost every cellular type, whereas IFITM5 is
expressed primarily in osteoblasts, as it is required for bone mineralization [4].
IFITMs are found mainly distributed at the plasma membrane and/or at endosomal mem-
branes. The IFITM1, 2, 3 and 5 genes are clustered on chromosome 11, and they encode for rel-
atively small proteins (about 130 amino acids) with both extra-cytoplasmic termini separated
by two transmembrane domains (TM1 and TM2) and a cytoplasmic loop (CIL) [3] [5]. TM1
and the CIL are well conserved between the IFITM proteins and a large group of members of
the CD225 protein family.
IFITM 1, 2, and 3 are currently known to inhibit the replication of multiple RNA viruses
that enter the host cell via endocytosis, including influenza A virus (IAV), West Nile virus
(WNV), Dengue virus (DENV) [6], severe acute respiratory syndrome coronavirus (SARS
CoV) and hepatitis C virus (HCV) [7]. In contrast, IFITMs do not inhibit the entry process of
mouse leukemia virus (MLV), Machupo virus (MACH), Lassa virus (LASV) or lymphocytic
choriomeningitis virus (LCMV) [4].
Little is known about the IFITM-mediated antiviral activity against DNA viruses. Only
IFITM1 has been recently described to inhibit Rana grylio virus (RGV), a frog/fish iridovirus,
at the entry stage [8]. On the other hand, IFITM1, 2 and 3 have been reported not to affect the
replication of other DNA viruses, such as human papillomavirus (HPV), human cytomegalovi-
rus (HCMV) and adenovirus 5 (Ad5) [9].
The antiviral effect of IFITMs is mainly exerted through their effects on the endocytic path-
way and would affect viruses entering the cell through a late endosomal compartment [4]. To
further expand our understanding on the antiviral activity of IFITMs against DNA viruses, we
investigated the role of these proteins in the replication cycle of the African swine fever virus
(ASFV), belonging to the nucleocytoplasmic large DNA virus (NCLDV) superfamily [10].
ASFV infection is strongly dependent on the endocytic pathway [11, 12], thus a possible
IFITM-mediated inhibition of the virus could likely occur in the endosomal compartments.
ASFV is the only member of the Asfarviridae family and is responsible of a highly lethal and
hemorrhagic disease affecting domestic swine, which often results in important economic
losses in many countries due to the high rate of mortality associated with the illness and the
lack of an effective vaccine [13]. An epidemic outbreak is currently affecting East Europe and is
slowly spreading between neighboring countries [14–16]. We previously reported that ASFV
enters into the host cell by dynamin-dependent and clathrin-mediated endocytosis [12, 17].
Thus, our goal in the current work was to test whether the IFITM family of proteins affected
early entry steps of ASFV infection in Vero cell cultures using the cell-adapted Ba71V isolate.
Materials and Methods
Cell culture and viruses
Vero cells were obtained from the American Type Culture Collection (ATCC, Richmond, VA,
USA) and maintained in Dulbecco modified Eagle medium supplemented with 5% fetal bovine
serum (FBS), 100 lU/ml penicillin, 100ug/ml streptomycin and 2mM L-glutamine at 37°C at
5% CO2. Cells were pretreated with 1,000 or 10,000 U/ml of universal type-I IFN (PBL Assay
Science) for 24 h, as indicated.
The tissue culture-adapted ASFV isolate Ba71V was used in most experiments [18]. For
flow cytometry analyses, a recombinant virus expressing the viral protein p54 fused to the
green fluorescent protein (GFP) was used (B54GFP) [19]. Preparation of viral stocks, titrations
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and infection procedures were carried out in Vero cells as previously described [18]. When
synchronization of viral infection was required, the adsorption phase took place at 4°C to allow
viral attachment to the cell surface but impeding its internalization. When indicated, ASFV
was semi-purified by sucrose cushion (40%) in PBS at 40,000xg for 50 min at 4°C.
Generation of stable cell lines
To generate stable cell lines expressing different proteins, the commercially available lentiviral
expression vector pLVX-Puro (Clontech) was used to clone the proteins of interest. 293T cells
were transfected at 100% confluency using Lipofectamine 2000 (Life technologies) with Opti-
MEM (Life technologies) in 10-cm2 plates. Plates were previously pretreated with poly-L-lysine
(Sigma-Aldrich) at a final concentration of 0.1 mg/ml to avoid cell detachment. Co-transfec-
tion of pLVX-puro expression vector together with vesicular stomatitis virus glycoprotein
(VSV-G) and the human immunodeficiency virus (HIV) gag-pol expressing plasmids was per-
formed to produce pseudotyped lentiviral vectors.
Supernatants containing the pseudotyped lentiviruses were collected twice at 48 h and 72 h
postransfection. Cell debris was removed by brief centrifugation at 1,000 rpm for 5 min and
cleared supernatants were 0.22 μM-filtered and stored at -80°C until use.
Sub-confluent Vero cells were transduced with the pseudotyped lentiviruses expressing the
gene of interest and supplemented with 1 μg/ml of polybrene (EMDMillipore). 24 h later,
transduced cells were selected by adding 8 μg/ml of puromycin (Life Technologies). Optimal
puromycin working concentration was previously titrated in non-transduced cells. Finally,
protein expression levels of Vero stable-cell lines were determined by Western Blot (WB).
Immunofluorescence
Cells were seeded and grown on glass coverslips. Mock-infected and infected cells were fixed
with 4% paraformaldehyde in PBS for 15 min at room temperature (RT). Following cell fixa-
tion, aldehyde fluorescence was quenched by incubation of cells with 50 mMNH4Cl in PBS for
10 min. Then, cells were permeabilized with PBS–0.1% Triton X-100 or Saponin (Sigma) for
10 min at RT.
After blocking with bovine serum albumin (BSA; Sigma) or normal goat serum (Sigma),
cells were stained with primary and secondary antibodies and then incubated with Topro-3
(Molecular Probes) in PBS at a 1:1,000 ratio for DNA staining. After washing, coverslips were
finally mounted on glass plates and cells were observed under a Leica TCS SP2-AOBS confocal
microscope (Leica-Microsystems, Wetzlar, Germany) using a 63X immersion oil objective.
To detect cholesterol distribution we used Filipin staining (Sigma), as previously described
[20]. Cholesterol was visualized in a conventional Leica DM RB microscope by combining a
63X immersion oil objective and a UV filter set. Images were captured with Leica Application
Suite advanced fluorescence software (LAS AF) and ImageJ software. Finally, digital images
were processed with Adobe Photoshop 8.0.
The primary antibodies used for immunofluorescence assays included the following: rabbit
polyclonal antibodies to IFITM1, IFITM2 and IFITM3 (Proteintech), 1:200; anti-ASFV p30
mouse monoclonal antibody, 1:100 (kindly given by Dr. J.M. Escribano, INIA); ASFV mouse
monoclonal antibodies anti-p72 (clone 1BC11 for immunofluorescence 1:1,000 or clone
18BG3 for WB 1:2,000) and anti-p150 (clone 17AH2, Ingenasa), 1:1,000; mouse monoclonal to
CD63 (Developmental Studies Hybridoma Bank, University of Iowa, clone H5C6), 1:200; rab-
bit polyclonal to Lamp1 (Abcam), 1:50; rabbit polyclonal to EEA1 and Rab7 (Cell Signalling),
1:50.
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Secondary antibodies were purchased fromMolecular Probes and diluted 1:200. Specificity
of labeling and absence of signal crossover were determined by examination of single labeled
control samples.
Western Blotting
Cells were harvested in Sample Buffer Laemmli 2X concentrate (Sigma). Then, the samples
were incubated for 5 min at 95°C and resolved by SDS-PAGE in 12% or 7% polyacrylamide-
bisacrylamide gels. Afterwards, separated proteins were transferred to a nitrocellulose mem-
brane (Bio-Rad) and the non-specific antibody binding sites were blocked with skimmed milk
diluted in PBS and then incubated with the specific primary and HRP (Horseradish peroxi-
dase)-conjugated secondary antibodies. Antibodies used for western blotting included: rabbit
polyclonal to IFITM1, IFITM2 and IFITM3 (Proteintech), 1:2,000; anti-ASFV p30 mouse
monoclonal antibody, 1:500; anti-ASFV p72 mouse monoclonal antibody (clone 1BC11, Inge-
nasa), 1:1,000, and mouse monoclonal to tubulin (Sigma-Aldrich), 1:2,000. As secondary anti-
body, anti-mouse IgG (GE Healthcare) or anti-rabbit IgG (Bio-Rad) conjugated to horseradish
peroxidase was used at a 1:5,000 dilution. Precision Protein StrepTactin-HRP Conjugate (Bio-
Rad) was used to reveal the ladder Precision Plus Protein WesternC (Bio-Rad). As a loading
control an anti-mouse antibody against β-tubulin (Sigma) was used, 1:2,000. Finally, bands
obtained after development with ECL reagent (GE Healthcare, Piscataway, NJ, USA) were
detected using a Chemidoc XRSplus Imaging System (Bio-Rad). Band densitometry was per-
formed with Image Lab software (Bio-Rad) and normalized to control values.
Detection and quantitation of the ASFV genome
The quantitation of the number of copies of ASFV genome was achieved by quantitative real-
time PCR (qPCR) using specific oligonucleotides and a Premix ExTaq (TM) (2X; Takara)
probe. Fluorescent hybridization probes were used to amplify a region of the p72 viral gene, as
described previously [21]. DNA from cells mock-infected or infected with ASFV Ba71V at
MOI of 1 pfu/cell was extracted at 16 hpi and purified with a DNAeasy blood and tissue kit
(Qiagen). DNA concentration was measured using Nanodrop. The amplification mixture was
prepared on ice as follows: 250 ng template DNA diluted in mQ H2O to a total volume of 7μl,
1 μl oligonucleotide OE3F (50 pmol), 1 μl oligonucleotide OE4R (50 pmol), 10 μl PCR Premix
Ex Taq(TM) (2X; Takara), 1 μl TaqMan probe SE2 (5 pmol) [21]. Positive amplification con-
trols included DNA purified from ASFV purified virions at different concentrations as stan-
dards. Negative amplification controls consisted in DNA from mock-infected cells. Each
sample was included in triplicates and values were normalized to standard positive controls.
Reactions were performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosys-
tems) with the following parameters: 1 cycle at 94°C for 10 min, 45 cycles at 94°C for 15 s, and
45 cycles at 58°C for 1 min.
Decapsidation assay
To study virion decapsidation in ASFV, a protocol was adapted from a previous publication
[22]. Briefly, stable cell lines Vero-IFITM1, IFITM2, IFITM3 or control cells containing the
empty vector were infected at MOI of 10 pfu/cell after viral synchronization at 4°C for 90
minutes to enable virus attachment to the cell but restricting viral entry. Infection was
allowed to proceed for 75 minutes at 37°C, 5% CO2. Cells were then washed with cold PBS
1X and treated with 0.05% trypsin-EDTA (Gibco) for 10 minutes at 37°C to remove the
membrane-bound virus. Finally, cells were placed in media containing FCS to quench trypsin
activity and washed with PBS. After this treatment, only internalized virions were observed
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in an immunofluorescence assay as described above. We used specific antibodies to detect
the major viral capsid protein p72 and the viral core protein p150, and staining was analyzed
by confocal microscopy. Decapsidated virions were single labeled for p150 and were counted
for each condition and normalized to the total number of fully encapsidated virions which
were double labeled for p72 and p150.
Flow cytometry
Stable cell lines Vero-IFITM1, IFITM2, IFITM3 or control cells containing the empty vector
were infected with Ba71V or B54GFP at the indicated MOI. Recombinant B54GFP is a recom-
binant ASFV expressing green fluorescent protein as a fusion protein of viral p54 [19]. Samples
infected with B54GFP at 16 hpi were just fixed and washed with FACs buffer three times before
analysis.
Vero cells infected with Ba71V at 6 hpi or 16 hpi (early or late postinfection times respec-
tively), were harvested by trypsinization, washed with FACS buffer (containing PBS, 0,01%
sodium azide, and 0,1% bovine serum albumin), fixed and permeabilized with Perm2 (BD sci-
ence) for 10 min at RT and finally incubated with specific primary antibodies against p30 and
p72 for 30 min at 4°C. The secondary antibody used was phycoerythrin (PE) conjugated
(DAKO) 1:50 diluted in FACS buffer for 30 min at 4°C. After repeated washes, 10,000 cells/
tube were analyzed in the FACSCalibur flow cytometer (BD Science) in triplicates. The
obtained infection rates were always normalized to the corresponding control.
Statistical analysis
Bonferroni’s multiple-comparison test was used to compare different experimental groups.
Prism software (GraphPad Software, Inc.) and INSTAT3 software were used for the statistical
analysis. Values were expressed in graph bars as mean ±SD of at least three independent exper-
iments unless otherwise noted. Metrics were normalized to control values and represented in
graphics. Asterisks denote statistically significant differences (p<0.001, p<0.01 and
p<0.05).
Results
IFN treatment abrogates ASFV infection
To determine the effect of interferon on ASFV infection, Vero cells were pretreated with 1,000
or 10,000 U/ml of universal type-I IFN (PBL Assay Science) and 24 h later, they were infected
with recombinant ASFV B54GFP at a MOI of 5 pfu/cell (Fig 1). Viral infection was quantified
by analyzing the number of GFP-positive cells by flow cytometry at 16 hpi (Fig 1A). Pretreat-
ment of Vero cells with universal type-I IFN at both concentrations completely abrogated
ASFV infectivity when compared to untreated control cells. A sample flow cytometry profile is
shown (Fig 1A).
IFN treatment induces expression of IFITM proteins
IFITM proteins are located in different cellular compartments and their antiviral properties
strongly correlate with their capacity to alter the fluidity and fusion ability of the membranes in
which they reside [23, 24]. Then, we analyzed IFITMs expression and distribution in Vero cells
upon IFN treatment. To this end, cells were incubated with either 1,000 or 10,000 U/ml of uni-
versal type-I IFN for 24 h and IFITMs 1, 2 and 3 distribution was analyzed by confocal micros-
copy (Fig 1B). Although basal levels of IFITM2 and 3 were detected prior to treatment with
DNA Virus Restriction by Antiviral IFITMs
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Fig 1. Effect of interferon and IFN-induced proteins IFITMs in ASFV infection. (A). ASFV-infected cells percentages analyzed by flow cytometry at 16 hpi
in Vero cells untreated or treated with IFN at 1,000U/ml or 10,000U/ml 24 h prior to infection and infected with recombinant ASFV B54GFP at a MOI of 5 pfu/
DNA Virus Restriction by Antiviral IFITMs
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IFN, both proteins were clearly overexpressed after treatment and presented a characteristic
vesicular distribution packed tightly to the nuclear area.
To further analyze the expression of IFITM1, 2 and 3 upon IFN treatment, Vero and 293T
cells were incubated with universal type-I IFN for 24 h and analyzed by WB (Fig 2). While
IFITM1 and IFITM2 were induced by IFN in both cell lines (Fig 2A and 2B), IFITM3 showed
the highest induction (Fig 2C).
Generation and validation of IFITM-expressing cell lines
In order to analyze the possible impact of IFITMs in ASFV infection, we generated Vero cells
stably expressing the human IFITM1, 2, 3 (hereinafter referred to as Vero-IFITM1, 2 or 3 cells
respectively) or control cells containing the empty vector. To generate the stable cell lines we
used a lentiviral transduction system. Our proteins of interest were cloned into the pLVX vec-
tor (see material and methods section for detailed experimental procedures). Positively trans-
duced Vero stable cells were selected with 8 μg/ml of puromycin. Once these cells were
established, the expression of different IFITM proteins was confirmed by WB analysis (Fig
3A). As shown in the corresponding WB densitometry (Fig 3B), the highest expression levels
within the IFITM family members corresponded to IFITM3, followed by IFITM2 and IFITM1.
After assessing the expression levels of the Vero-IFITM cells, we next wanted to ascertain
the subcellular distribution of each IFITM. Expression of IFITM1, 2 and 3 in Vero-IFITM cells
was compared with the distribution of IFITMs in Vero cells with the empty vector. Confocal
microscopy experiments revealed that, IFITM1 was mainly distributed at the plasma mem-
brane and to a lesser extent in perinuclear compartments, resembling endosomal structures
(Fig 3C, lower left panel), while endogenous IFITM1 was barely detected in Vero cells contain-
ing the empty vector (Fig 3C, upper left panel).
In Vero-IFITM2 cells, overexpression led to a high accumulation of the protein in the peri-
nuclear region, colocalizing with vesicular structures that resembled endosomes (Fig 3C,
medium lower panel). Consistent with Fig 1B, there was a significant expression of endogenous
IFITM2 in control Vero cells containing the empty vector, which displayed a mitochondria-
like pattern together with vesicular-like structures.
Finally, overexpressed IFITM3 was found predominantly accumulated in the perinuclear
region, showing a pattern consistent with localization at clustered endosomal structures (Fig
3C, lower right panel). Endogenous IFITM3 was barely detected in Vero cells containing the
empty vector (Fig 3C, upper right panel).
Analysis of endogenous IFITM2 expression in control Vero cells suggested a mixed mito-
chondrial and vesicular pattern. To confirm this observation, we analyzed subcellular localization
of IFITM2 using Mitotracker Red as a specific marker for mitochondria. Confocal images
revealed a distribution of IFITM2 to mitochondrial structures in cells containing the empty vec-
tor (Fig 4). However, in Vero-IFITM2 cells, IFITM2 labelling localized to endosomal-like struc-
tures and we found few areas of colocalization between IFITM2 and mitochondria (Fig 1B).
IFITM2 and IFITM3 alter distribution of endosomal compartments
Then, we investigated the possible mechanism underlying the inhibition caused by IFITM in
the viral infection. To further analyze the vesicular localization of IFITMs, we studied the
cell. Data are expressed as mean±SD of three independent experiments. Statistical significance was evaluated by one-way ANOVA followed by Bonferroni’s
multiple comparison test. Differences are marked with asterisks as indicated (***p<0.001). An example of a typical FACS profile is shown. (B). Confocal
fluorescence images of IFITM1, 2 and 3 subcellular distribution in untreated Vero cells or upon increasing universal IFN concentrations (1,000 or 10,000U/ml)
for 24 h. Bar = 10μm.
doi:10.1371/journal.pone.0154366.g001
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Fig 2. Expression of IFITM proteins upon interferon induction. Expression of IFITM proteins was induced in Vero and 293T cells after treatment with
Universal type-I IFN at both 1,000 or 10,000 U/ml concentrations for 24 h and compared with untreated cells. Total cell extracts were incubated with
antibodies against IFITM1 (A), IFITM2 (B) and IFITM3 (C). Right side panels represent WB quantification by densitometry for each IFITM and are expressed
as the mean±SD from three independent experiments. Statistical significance was evaluated by a one-way ANOVA followed by Bonferroni’s multiple
comparison test. Differences are marked with asterisks as indicated (**p<0.01; ***p<0.001).
doi:10.1371/journal.pone.0154366.g002
DNA Virus Restriction by Antiviral IFITMs
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expression of endosomal markers EEA1 (early endosomes; EE), CD63 (multivesicular bodies;
MVB), Rab7 (late endosomes; LE) and Lamp1 (lysosomes; LY) in Vero-IFITM cells or control
cells containing the empty vector (Fig 5A). Endosomes are normally distributed through the
cytoplasm and this dispersed distribution was found for the different maturation stages of
endosomes in controls and in Vero-IFITM1 cells. However, in Vero-IFITM2 and IFITM3 cells
dispersed distribution changed and endosomes aggregated around the nucleus (Fig 5A). This
endosome redistribution was analyzed by confocal microcopy in x, y, z planes by measuring
Fig 3. Validation of IFITM-expressing cell lines. (A). Western blot of Vero cell lines expressing IFITM1, 2 and 3. (B). Graphics depict mean±SD of the
densitometry values relative to load control tubulin from three independent experiments. Statistical significance was evaluated by a one-way ANOVA
followed by Bonferroni’s multiple comparison test. Differences are marked with asterisks as indicated (***p<0.001). (C). Subcellular distribution of IFITM in
stable cell lines analyzed by confocal microscopy and compared to control cells containing the empty vector. Bar = 10μm.
doi:10.1371/journal.pone.0154366.g003
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the mean distance between each endosomal marker and the cell nucleus, using the “Distance
Measure” ImageJ plug-in (Fig 5B). A total of 30 cells were analyzed for each condition.
We concluded that overexpression of IFITM2 and IFITM3 altered endosome distribution
by accumulating these vesicles to the perinuclear region, similar to the pattern previously
found after IFN treatment of Vero cells (Fig 1B) and this redistribution might reflect alterations
in endo-lysosomal maturation and function.
Colocalization of IFITMs with endosomal compartments
Next, we analyzed the colocalization rate between IFITMs and endosomal structures. CD63
remains mainly associated with intracellular vesicular membranes and it is particularly abun-
dant in endosomal structures called multivesicular bodies (MVBs), which constitute a late and
acidic endosomal compartment filled with intraluminal vesicles (ILVs). These ILVs are filled
with cholesterol and are crucial for endosomal membrane backfusion and necessary for late
endosome maturation.
Co-staining of IFITMs and CD63 by immunofluorescence assay revealed a clear colocaliza-
tion of IFITMs and CD63 in Vero-IFITM cells, with 75% colocalization for Vero-IFITM2 cells
and 40% in Vero-IFITM1 and in IFITM3 cells (Fig 6A). Then, IFITM2, and to a lesser extent
Fig 4. Differences in subcellular localization between endogenous and exogenous IFITM2. Expression of IFITM2 (green) was analyzed in Vero-IFITM2
cells and Vero cells containing the empty vector. Mitochondrial structures were marked with Mitotracker (red) to highlight their marked colocalization with
IFITM2, especially in cells containing the empty vector. Bar = 10 μm.
doi:10.1371/journal.pone.0154366.g004
DNA Virus Restriction by Antiviral IFITMs
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IFITM1 and 3, were located primarily in endosomal compartments as indicated by higher colo-
calization with endosomal marker CD63 (Fig 6C) when compared to the empty vector (Fig
6B).
IFITM2 and IFITM3 induce accumulation of cholesterol in endosomal
compartments
IFITM proteins could reduce curvature of cell membranes for fusion pore formation [24, 25] at
the outer endosomal membrane, also called endosomal-limiting membrane, to differentiate it
from the membranes of intraluminal vesicles inside multivesicular bodies (MVB/LE). This
would lead to an alteration of membrane fusion and impaired cholesterol endosomal efflux.
Changes in endosomal distribution such as those found in IFITM stably expressing cells (Fig 5)
is a characteristic phenotype of an altered cholesterol endosomal efflux [23, 26]. Conversely, a
conserved endosomal cholesterol efflux is required for a correct endosomal function. There-
fore, we analyzed intracellular and intra-endosomal cholesterol levels by using the cholesterol
marker filipin. Vero-IFITM2 and IFITM3 cells showed intense intracellular cholesterol accu-
mulation at the perinuclear area (Fig 7A) that was absent in control cells containing the empty
vector (Fig 7B). This cholesterol accumulation also colocalized with the IFITM-labeled endoso-
mal vesicles. In contrast, in Vero-IFITM1 cells, only discrete colocalization areas between
IFITM1 and cholesterol were found at the plasma membrane.
Collectively, these findings indicate that IFITM2 and IFITM3 overexpression in Vero cells
results in cholesterol accumulation in endosomal compartments, and as a result it might be
responsible of an altered endosomal function possibly altering viral entry through this
pathway.
IFITM2 and IFITM3 proteins restrict ASFV entry
Next, we investigated whether overexpression of IFITMs could restrict ASFV infection or not.
ASFV is known to require acidic endosomal compartments for entry into host cells. Successful
ASFV entry and egress from endosomes depends on the acidic pH of late endosomes [11]. Pre-
vious experiments in the laboratory revealed that the inhibition of acidification impaired viral
decapsidation and viral particles were retained in Rab7-positive late endosomes, thus blocking
viral infection progression [11]. Given that IFITM restriction could be mediated at the endocy-
tic pathway [1, 4], we hypothesized that IFITM overexpression may affect virus entry process
and subsequent ASFV infection.
Acidic pH of late endosomal compartments is required for viral decapsidation, which is the
first step required for uncoating previous to endosomal escape of the virus and the start of rep-
lication [11]. The ASF virion is composed of several concentric domains. The viral capsid is
formed by major capsid protein p72 organized in capsomers. Hence, after decapsidation, p72
staining of virions is lost. The internal core is composed by the nucleoid containing genome
coated by the core shell, a thick protein layer that can be labeled with antibodies against p150, a
core shell protein derived from processed core shell polypeptides [27].
Fig 5. IFITM expression induces a redistribution of endosomal compartments. (A). Confocal microscopy images of Vero-IFITM cells or controls
containing the empty vector stained with endosomal markers EEA1 (EE), CD63 (MVB), Rab7 (LE) and Lamp1 (LY). Endosomes were predominantly
dispersed in the cytoplasm of cells containing the empty vector or concentrated to the perinuclear area in Vero-IFITM2 and 3 cells. (B). The change in
distribution was quantified by measuring the mean distance to the nucleus of the different endosomal markers in x, y and z planes as described in materials
and methods section. As shown in graphics, distance was reduced in Vero-IFITM2 and 3 cells. Graphics depict mean±SD of N = 30 cells per condition.
Statistical significance was evaluated by a one-way ANOVA followed by Bonferroni’s multiple comparison test. Differences are marked with asterisks as
indicated (*p<0.05; **p<0.01).
doi:10.1371/journal.pone.0154366.g005
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We used antibodies against the major viral capsid protein p72 to detect viral capsids and
against viral core protein p150 to detect viral cores (Fig 8). We analyzed the number of encapsi-
dated viral particles, double labeled for p72 and p150, and compared with the number of suc-
cessfully decapsidated viral cores positive for p150 at 75 minutes postinfection (mpi). At this
time point, most virions undergo uncoating and progress to replication in normal conditions,
otherwise, encapsidated virions would accumulate. Confocal microscopy revealed that the
number of viral cores was severely decreased in Vero-IFITM2 cells when compared to control
Fig 6. Colocalization of IFITMs with endosomal compartments. (A). Expression of IFITM1, 2 and 3 proteins (green) and CD63-positive late endosomes
(red) in Vero-IFITM cells or cells containing the empty vector. (B). Distribution of IFITM2 (green) and CD63 (red) in cells containing the empty vector.
Bar = 10μm. (C). Data were plotted on graphics representing the colocalization values between IFITM2 and endosomes in Vero-IFITM2 relative to control
cells of N = 30 cells per condition. Statistical significance was evaluated by a one-way ANOVA followed by Bonferroni’s multiple comparison test. Differences
are marked with asterisks as indicated (***p<0.001).
doi:10.1371/journal.pone.0154366.g006
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cells containing the empty vector (Fig 8B). Double-labeled encapsidated viral particles were
counted and the ratio of decapsidated viral cores compared to the total number of virions per
individual cell was calculated and expressed in percentages (Fig 8A). The percentage of decap-
sidated virus severely decreased under IFITM2 expression. However, IFITM3 expression pro-
duced an accumulation of virions leading to higher numbers of total virions (Fig 8C). This
increase in the number of total virions might be the result of an impaired progression of the
ASFV replication cycle. These virions would neither proceed with infection nor be degraded
and this would be consistent with an inhibition of the membrane fusion capacity at the endoso-
mal level. Altogether, these results indicate that viral entry was the rate-limiting step in Vero-
IFITM2 and IFITM3 cells for ASFV infectivity.
Fig 7. IFITM3 and 2 induce accumulation of cholesterol in endosomal compartments. (A). Analysis of cholesterol distribution using the specific marker
filipin (red) in Vero-IFITM1, 2 and 3 cells (green) and cells containing the empty vector. Cholesterol is accumulated in endosomes upon expression of IFITM2
and 3. (B). Basal IFITM2 expression in control cells containing the empty vector did not produce cholesterol accumulation. N = 30 cells per condition.
Bar = 10μm.
doi:10.1371/journal.pone.0154366.g007
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IFITMs impair ASFV infectivity
Finally, we analyzed the impact of IFITM expression on other infection parameters to find
reduced number of copies of ASFV genome at 16 hpi (Fig 9A). IFITM overexpression induced
a consistent reduction in infectivity as measured by early protein p30 expression by flow
cytometry (Fig 9B). However, these reductions were even more marked when analyzing
infected cell percentages by late p72 protein expression (Fig 9C). Finally, we also analyzed viral
protein expression by WB (Fig 9D–9F). The expression of protein p30 at 6 hpi (Fig 9D) and
p72 at 16 hpi (Fig 9E) resulted significantly reduced as other infection parameters.
Discussion
In the present work, we have studied the antiviral effect of the IFITM family of proteins in the
context of cell-adapted ASFV infection in Vero cells. While different IFITM proteins have been
repeatedly described as inhibitors of a broad spectrum of RNA viruses [6], their antiviral role
Fig 8. IFITM2 and IFITM3 restrict ASFV entry. (A). Analysis of the decapsidated virions in Vero-IFITM2 and IFITM3 compared to Vero control cells
containing the empty vector. IFITM2 significantly decreased numbers of decapsidated virions. Graphics show the percentage of decapsidated virions relative
to controls. Statistical significance was evaluated by a one-way ANOVA followed by Bonferroni’s multiple comparison test. Differences are marked with
asterisks as indicated (***p<0.001). (B). Confocal microscopy images of ASFV virions labelled for viral major capsid protein p72 (red) and inner core protein
p150 (green) upon expression of IFITM2, IFITM3 or empty vector. Positive virions for both proteins yielded a yellow signal and are shown encircled.
Bar = 10μm. (C). Graphical representation showing the ratio of decapsidated and encapsidated virions in Vero-IFITM2, IFITM3 or empty control cells related
to the total number of virions counted from a total of N = 15 cells per condition.
doi:10.1371/journal.pone.0154366.g008
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involving DNA viruses is poorly studied and only reported in the Rana grylio virus (RGV),
blocking the virions at the entry stage into the host cell [8].
ASFV Ba71V infection in Vero cells is significantly affected upon IFN treatment [28, 29]. In
general, the sensitivity towards the induction of the innate immune response of the host cell
has led viruses to acquire different strategies to regulate the IFN pathway for its own benefit.
Such is the case of ASFV viral gene A276R, which negatively regulates the induction of IFN
through targeting IRF3 in a NFκB-independent manner [30]. Another example is the ASFV
gene I329L, which codifies for a viral TLR3 homolog with inhibitory activity against IFN [31].
Finally, the myxovirus resistance gene A (MxA), which is another Interferon Stimulated Gene
(ISG), also inhibits the replication and the late gene expression of ASFV [32].
We report here that upon IFN treatment of Vero cells, the distribution of IFITM proteins
changes into a perinuclear vesicular pattern resembling endosomes. Our analysis of endoge-
nous IFITM2 expression in the absence of IFN induction showed colocalization with mito-
chondrial structures. Interestingly, IFITM2 underwent vesicular pattern redistribution around
the cell nucleus when overexpressed and upon IFN treatment as well.
Our characterization of the cellular distribution of IFITM1, 2 and 3 also unveiled specific
localization patterns linked to the endosomal pathway upon overexpression, particularly in the
late endosomal compartments. This distribution is coincident with previously reported data of
other groups, which described localization of endogenous IFITM1 at the plasma membrane
and early endosomes, and of IFITM2 and IFITM3 in late endosomes and lysosomes [33, 34].
Interestingly, overexpression of IFITM1 has been recently described to delay the proteolytic
degradation of human papilloma virus (HPV) capsids in keratinocytes [9]. This, however, did
not affect the replication of the virus.
Fig 9. General impact of IFITM overexpression in several infection parameters. (A). Quantitation of ASFV viral DNA at 16 hpi in Vero-IFITM cells
compared to empty controls. (B-C). Flow cytometry analysis showing percentages of infected Vero-IFITM cells at a MOI of 1 pfu/cell relative to empty controls
evaluated by early p30 expression at 6 hpi (B) or late p72 protein expression at 16 hpi. (D-E). Viral protein expression in IFITM expressing cells. Vero-IFITMs
and empty control cells were infected at a MOI of 1 pfu/cell. WB quantification of early p30 expression at 6 hpi (D) and late p72 expression at 16 hpi (E). (F).
Western blot images of previous panels D and E. (A-E). Graphics depict mean±SD of densitometry values from three independent experiments. Statistically
significance was evaluated by a one-way ANOVA followed by Bonferroni’s multiple comparison test. Differences are marked with asterisks as indicated
(*p<0.05; **p<0.01; ***p<0.001).
doi:10.1371/journal.pone.0154366.g009
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Our analysis of ASFV Ba71V uncoating correlated the expression of IFITM2 with a decrease
in the numbers of decapsidated ASF virions in Vero cells. This suggests a possible role for
IFITM2 in inhibiting ASFV exit from late endosomes. In contrast, IFITM3 did not modify the
ratio between encapsidated and decapsidated virions. Instead, IFITM3 apparently increased
the accumulation of virions that are probably retained and do not proceed to degradation and/
or to a productive infection. These results may also suggest that the presence of IFITM3 affects
the release of the virions from the late endosomal compartments.
ASFV enters into the host cell by dynamin-dependent and clathrin-mediated endocytosis
[12, 17] and macropinocytosis [35]. In fact, endosomal pathway integrity is known to be
important for ASFV infection, both for culture-adapted isolates in cell lines [11] or for virulent
and attenuated isolates in primary macrophages [12]. Hence, it is not surprising that infection
could be impaired by these restriction factors acting at the endosomal membrane.
The aforementioned IFITM2- and IFITM3-mediated inhibition of ASFV entry has been
previously reported in other viruses, including IAV, flaviviruses (DENV andWNV) [6], filovi-
ruses (MARV and EBOV) and coronaviruses (such as SARS) [34]. In contrast, infection with
alphaviruses, arenaviruses and MLV (a retrovirus) seems to be unaffected by IFITM protein
expression [4]. In general, IFITM-mediated viral inhibition has been related to impaired viral-
host membrane fusion subsequent to viral binding and endocytosis [33, 34]. IFITM3 has also
been reported to modulate the fluidity and the bending modulus of the cell membrane, thus
making it resistant to viral fusion machinery [36].
We also studied whether the inhibition of ASFV entry could be due to an alteration of the
endosomal compartments. Analysis of endosome distribution upon IFITM overexpression
revealed that IFITM2 and IFITM3 altered the normal distribution of early and late endosomes
and lysosomes. However, this alteration was not found in the presence of IFITM1. A collapse
of endosomes to the perinuclear area is also a characteristic phenotype of an alteration of endo-
somal cholesterol efflux [26]. Also, recent publications from our laboratory demonstrated that
accumulation of cholesterol in endosomes caused by a chemical inhibition of cholesterol flux,
causes virion retention inside endosomes and inhibition of infection progression [37].
There are currently two proposed models trying to explain the IFITM-mediated inhibition
of viral entry. The first one, known as the “tough membrane”model, postulates that intramem-
branous interactions between adjacent IFITMs alter the fluidity and bending of the host cellu-
lar membrane, making it resistant to the viral fusion machinery [36]. The second model
suggests that IFITMs can induce the accumulation of cholesterol in the endosomal membrane
and membrane fusion defects [38] disturbing intracellular cholesterol homeostasis that finally
blocks the viral release into cytosol [23].
IFITM2 and IFITM3 have been previously reported to alter the cholesterol homeostasis at
the late endosome, leading to cholesterol accumulation and blocking the viral release [23]. In
the present study, we have described accumulation of cholesterol upon overexpression of
IFITM2 and IFITM3. We have recently reported that inhibition of cholesterol exit from endo-
somes using chemical inhibitors causes retention of virions inside these vesicles, thus impairing
progression of the infection [37]. Altogether these data could suggest that the antiviral action
of IFITMs may affect to a higher extent to those viruses that require the endosomal pathway
during the early stages of infection.
Collectively, our results illustrate a close relationship between the IFITM protein family and
the endosomal pathway, leading to the inhibition of ASFV infection. The antiviral action of
IFITMs could rely on alterations of the endosomal physiology and ongoing studies in our labo-
ratory will be focused on antiviral targets at the molecular regulation of late endosomes. Also, a
role in cell-to-cell viral transmission has been postulated for IFITMs, which are incorporated
into HIV-1 virions [39].
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We have performed this study in a cellular system using the cell-adapted Ba71V isolate in
Vero cells but these results will be next extended to other ASFV isolates with porcine macro-
phages. Further studies will be required for better understanding the relevance of IFITMs in
the context of ASFV infection. In summary, IFITMs represent a broad and previously unappre-
ciated class of restriction factors that degrade invading enveloped viruses and may therefore be
considered as potential antiviral components to protect the host cell.
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